Inhibikase Therapeutics, Inc. — All Filings
330 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
3
3/A
4
4/A
424B3
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DEFR14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
PRE 14A
RW
S-1
S-1/A
S-1MEF
S-3
S-3/A
S-8
SC 13D
SC 13G
SC 13G/A
SC 14F1
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| S-8 | S-8 | 0001193125-26-126573 | Mar 26, 2026 | — |
| 10-K | 10-K | 0001193125-26-126371 | Mar 26, 2026 | Dec 31, 2025 |
| 8-K | 8-K | 0001193125-26-126322 | Mar 26, 2026 | — |
| 4 | 4 | 0001193125-26-068079 | Feb 24, 2026 | Feb 21, 2026 |
| 4 | 4 | 0001193125-26-068077 | Feb 24, 2026 | Feb 21, 2026 |
| 4 | 4 | 0001193125-26-068063 | Feb 24, 2026 | Feb 21, 2026 |
| SCHEDULE 13G/A | — | 0001104659-26-016623 | Feb 17, 2026 | — |
| SCHEDULE 13G/A | — | 0001104659-26-016478 | Feb 17, 2026 | — |
| SCHEDULE 13G/A | — | 0001193125-26-054524 | Feb 17, 2026 | — |
| SCHEDULE 13G/A | — | 0001104659-26-015334 | Feb 13, 2026 | — |
| SCHEDULE 13G/A | — | 0001875620-26-000002 | Feb 13, 2026 | — |
| 4 | 4 | 0001193125-26-006351 | Jan 7, 2026 | Jan 5, 2026 |
| 4 | 4 | 0001193125-26-006350 | Jan 7, 2026 | Jan 5, 2026 |
| 4 | 4 | 0001193125-26-006343 | Jan 7, 2026 | Jan 5, 2026 |
| SCHEDULE 13G | — | 0001493152-25-029834 | Dec 31, 2025 | — |
| 8-K | 8-K | 0001193125-25-326916 | Dec 19, 2025 | — |
| 424B5 | 424B5 | 0001193125-25-326883 | Dec 19, 2025 | — |
| 4 | PRIMARY DOCUMENT | 0001875620-25-000025 | Nov 24, 2025 | Nov 21, 2025 |
| 8-K | 8-K | 0001193125-25-291443 | Nov 21, 2025 | Nov 20, 2025 |
| 424B5 | 424B5 | 0001193125-25-291433 | Nov 21, 2025 | — |
| 424B5 | 424B5 | 0001193125-25-289894 | Nov 20, 2025 | — |
| 8-K | 8-K | 0001193125-25-289768 | Nov 20, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-283169 | Nov 14, 2025 | Sep 30, 2025 |
| 8-K | 8-K | 0001193125-25-283075 | Nov 14, 2025 | — |
| 3/A | 3/A | 0001193125-25-191465 | Aug 28, 2025 | Feb 21, 2025 |
| 3/A | 3/A | 0001193125-25-191464 | Aug 28, 2025 | Feb 21, 2025 |
| 4 | 4 | 0001193125-25-191463 | Aug 28, 2025 | Feb 21, 2025 |
| SCHEDULE 13G/A | — | 0001104659-25-078859 | Aug 14, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-180899 | Aug 14, 2025 | Jun 30, 2025 |
| 8-K | 8-K | 0001193125-25-180889 | Aug 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001875620-25-000021 | Aug 13, 2025 | — |
| 3/A | PRIMARY DOCUMENT | 0001875620-25-000002 | Jul 15, 2025 | Jun 6, 2025 |
| 4/A | 4/A | 0000950170-25-093445 | Jul 2, 2025 | Feb 21, 2025 |
| 4/A | 4/A | 0000950170-25-093441 | Jul 2, 2025 | Feb 21, 2025 |
| 4/A | 4/A | 0000950170-25-093440 | Jul 2, 2025 | Feb 21, 2025 |
| 4 | 4 | 0000950170-25-093436 | Jul 2, 2025 | Jun 30, 2025 |
| 4 | 4 | 0000950170-25-093434 | Jul 2, 2025 | Jun 30, 2025 |
| 4 | 4 | 0000950170-25-093432 | Jul 2, 2025 | Jun 30, 2025 |
| 4 | 4 | 0000950170-25-093430 | Jul 2, 2025 | Jun 30, 2025 |
| 4 | 4 | 0000950170-25-093428 | Jul 2, 2025 | Jun 30, 2025 |
| 4 | 4 | 0000950170-25-093424 | Jul 2, 2025 | Jun 30, 2025 |
| 8-K | 8-K | 0001193125-25-152767 | Jun 30, 2025 | Jun 27, 2025 |
| EFFECT | — | 9999999995-25-002070 | Jun 27, 2025 | — |
| CORRESP | — | 0001193125-25-146877 | Jun 25, 2025 | — |
| UPLOAD | — | 0000000000-25-006615 | Jun 25, 2025 | — |
| S-3 | S-3 | 0001193125-25-143738 | Jun 20, 2025 | — |
| DEFA14A | DEFA14A | 0001193125-25-139929 | Jun 12, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-071635 | May 14, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0001193125-25-119939 | May 14, 2025 | — |
| ARS | ARS | 0000950170-25-069236 | May 12, 2025 | Dec 31, 2024 |